Formulation of PLGA Polymeric Nanosuspension containing Pramipexole Dihydrochloride for improved treatment of Parkinson's Diseases

Somasundaram, I.; Yadav, Bhuneshwar; Kumar, S. Sathesh

doi:10.5958/0974-360x.2016.00155.4

Cited by 13 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies showed that PPX-loaded NPs inhibit the TBARS levels in RT-induced mice. 59 Here, it is observed that the PPX−PVP−CuO NC strongly inhibited the TBARS level in RT-exposed flies. In various mechanisms, protein carbonylation was observed, including the conjugation of an aldehyde with the amine group of amino acids to become a product of conjugated lipids.…”

Section: Determination Of Acetylcholinesterase Activitymentioning

confidence: 64%

Polyvinylpyrrolidone-Capped Copper Oxide Nanoparticles-Anchored Pramipexole Attenuates the Rotenone-Induced Phenotypes in a Drosophila Parkinson’s Disease Model

Hanumanthappa,

Venugopal,

P C

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive, age-related neurodegenerative disease. The disease is characterized by the loss of dopaminergic neurons in the substantia nigra, pars compacta of the midbrain. Pramipexole (PPX) is a novel drug used for the treatment of PD. It has a high affinity for the dopamine (DA) D2 receptor subfamily and acts as a targeted mitochondrial antioxidant. It is less effective in the treatment of PD due to its short half-life, highly inconvenient dosing schedule, and long-term side effects. In recent years, PPX-loaded nanoformulations have been actively reported to overcome these limitations. In the current study, we focused on increasing the effectiveness of PPX by minimizing the dosing frequency and improving the treatment strategy for PD. Herein, we report the synthesis of biodegradable polyvinylpyrrolidone (PVP)-capped copper oxide nanoparticles (PVP–CuO NPs), followed by PPX anchoring on the surface of the PVP–CuO NPs (PPX–PVP–CuO NC), in a simple and inexpensive method. The newly formulated PPX–PVP–CuO NC complex was analyzed for its chemical and physical properties. The PPX–PVP–CuO NC was tested to protect against rotenone (RT)-induced toxicity in the Drosophila PD model. The in vivo studies using the RT-induced Drosophila PD model showed significant changes in negative geotaxis behavior and the level of DA and acetylcholinesterase. In addition, oxidative stress markers such as glutathione- S -transferase, total glutathione, thiobarbituric acid reactive species, and protein carbonyl content showed significant amelioration. The positive changes of PPX–PVP–CuO NC treatment in behavior, neurotransmitter level, and antioxidant level suggest its potential role in mitigating the PD phenotype. The formulation can be used for treatment or pharmacological intervention against PD.

show abstract

Section: Determination Of Acetylcholinesterase Activitymentioning

confidence: 64%

Polyvinylpyrrolidone-Capped Copper Oxide Nanoparticles-Anchored Pramipexole Attenuates the Rotenone-Induced Phenotypes in a Drosophila Parkinson’s Disease Model

Hanumanthappa,

Venugopal,

P C

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

“…Table shows the potential therapeutic effects of nanophytomedicines in the 24 studies that involved in vivo PD models. Parkinsonism or PD-related symptoms were induced using neurotoxins, of which MPP + − ,,− ,,− or rotenone ,− were the most common. The in vivo models that were treated with neurotoxins included rats, ,,,,− ,, mice, ,− ,,− , zebrafish, , and Drosophila melanogaster .…”

Section: Use Of Nano-phytomedicine In Pdmentioning

confidence: 99%

Nanophytomedicines as Therapeutic Agents for Parkinson’s Disease

Burns,

Buck,

D’ Souza

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Phytochemicals are promising therapeutics for various neurodegenerative disorders, including Parkinson's disease (PD). However, their efficacy, pharmacokinetic properties, and penetration across the blood−brain barrier can be improved using delivery systems such as nanoparticles. We reviewed recently published work in which nanoparticles were used to deliver phytochemicals toward PD treatment. The studies show that nanoparticles not only improve the pharmacological effect of the phytochemicals but also enable targeting to the brain and crossing of the blood−brain barrier. Various ligands were added to the nanoparticles to improve blood−brain barrier transportation. The promising findings from the published studies reveal that more research into nanophytomedicine approaches as therapeutic targets for PD is warranted, especially since they have the potential to protect against key features of PD, including α-synuclein aggregation, mitochondrial dysfunction, and dopaminergic neuronal death. Furthermore, future directions should involve smart designs to tailor nanoparticles for improved therapeutic delivery by modifying their features, such as architecture, surface and material properties, targeting ligands, and responsiveness.

show abstract

“…PLGA and Pluronic F68 were used to make a nanosuspension of Pramipexole dihydrochloride using a modified nanoprecipitation method. [16] It is used as a brain-targeting drug. The prepared drug was evaluated using a Fourier transform infrared (FTIR) spectrophotometer; the FTIR spectrum of Pramipexole dihydrochloride, polymer, and a mixture of both drugs and the polymer was obtained using the KBr pellet technique.…”

Section: Drug Loaded Plga Nanoparticlesmentioning

confidence: 99%

Untitled

Kumar¹

2021

AJP

View full text Add to dashboard Cite

Formulation of PLGA Polymeric Nanosuspension containing Pramipexole Dihydrochloride for improved treatment of Parkinson's Diseases

Cited by 13 publications

References 0 publications

Polyvinylpyrrolidone-Capped Copper Oxide Nanoparticles-Anchored Pramipexole Attenuates the Rotenone-Induced Phenotypes in a Drosophila Parkinson’s Disease Model

Polyvinylpyrrolidone-Capped Copper Oxide Nanoparticles-Anchored Pramipexole Attenuates the Rotenone-Induced Phenotypes in a Drosophila Parkinson’s Disease Model

Nanophytomedicines as Therapeutic Agents for Parkinson’s Disease

Untitled

Contact Info

Product

Resources

About